CRL Exam Study 226 ACTUAL
EXAM 2026/2027 | CRL Certification
Complete Review | Verified Q&A |
Pass Guaranteed - A+ Graded
Section 1: Research Regulations & Ethics
Q1: The Belmont Report outlines three core ethical principles for the protection of human subjects.
Which principle requires that subjects be treated as autonomous agents and that persons with
diminished autonomy be protected?
A. Beneficence
B. Justice
C. Respect for Persons [CORRECT]
D. Non-maleficence
Correct Answer: C
Rationale: The Belmont Report defines "Respect for Persons" as having two components: treating
individuals as autonomous agents and providing extra protection for those with diminished autonomy
(e.g., children, prisoners). Beneficence relates to maximizing benefits and minimizing harms. Justice
relates to the fair distribution of the burdens and benefits of research. Board Strategy: Respect =
Autonomy.
Q2: According to ICH E6(R2) GCP guidelines, which party has the ultimate responsibility for the conduct
of a clinical trial at the site level?
A. The Sponsor
B. The Clinical Research Associate (CRA)
,C. The Institutional Review Board (IRB)
D. The Principal Investigator (PI) [CORRECT]
Correct Answer: D
Rationale: While the Sponsor is responsible for the overall trial, the Principal Investigator (PI) is
responsible for the conduct of the trial at their specific site. This includes the delegation of tasks,
oversight of staff, and protection of subjects. The IRB oversees ethics, not conduct. Board Strategy: Site
responsibility = PI.
Q3: A clinical trial subject calls the coordinator and states, "I want to stop the study." What is the
coordinator's most appropriate response?
A. "You have signed a contract; you must complete the study."
B. "You have the right to withdraw from the study at any time without penalty or loss of benefits to
which you are otherwise entitled." [CORRECT]
C. "You must come in for one final safety check before you can stop."
D. "I will have to report you to the Sponsor for protocol deviation."
Correct Answer: B
Rationale: A fundamental principle of GCP and the Declaration of Helsinki is that a subject can withdraw
from a study at any time for any reason without penalty. Requiring additional visits or threatening the
subject violates their rights. Board Strategy: Subject autonomy always comes first.
Q4: Which document serves as the basis for an investigator's financial disclosure?
A. Form FDA 1572 [CORRECT]
B. Form FDA 483
C. The Delegation Log
D. The Site Initiation Report
,Correct Answer: A
Rationale: Form FDA 1572 (Statement of Investigator) includes a section where the investigator discloses
financial interests that could affect the study's integrity. This form commits the investigator to follow
regulations and the protocol. Board Strategy: FDA 1572 = Investigator commitment & Financial
Disclosure.
Q5: Under 21 CFR Part 50, which of the following is a required element of Informed Consent?
A. A statement that the study involves no risk.
B. An explanation of the compensation available if injury occurs. [CORRECT]
C. A guarantee of the drug's efficacy.
D. The names of all other study participants.
Correct Answer: B
Rationale: The 8 required elements of informed consent include an explanation of whether
compensation or medical treatment is available if injury occurs. There is no such thing as "no risk,"
efficacy is never guaranteed, and other participants' names are confidential. Board Strategy: Memorize
the 8 basic elements of consent.
Q6: What is the primary purpose of an Institutional Review Board (IRB)?
A. To ensure the scientific validity of the protocol.
B. To protect the rights, safety, and well-being of human subjects. [CORRECT]
C. To manage the financial aspects of the trial.
D. To recruit subjects for the study.
Correct Answer: B
Rationale: The IRB (or Ethics Committee) acts as a subject advocate. Their primary function is ethical
review to ensure subjects are protected. Scientific validity is the Sponsor's primary duty (though IRBs
review it for ethics). Board Strategy: IRB = Subject Protection.
, Q7: A monitor discovers that a PI is enrolling subjects who do not meet the inclusion criteria. This is
classified as:
A. A Protocol Deviation.
B. A Protocol Violation. [CORRECT]
C. An Adverse Event.
D. An Amendment.
Correct Answer: B
Rationale: A violation is a serious departure from the protocol that affects the subject's rights, safety, or
data integrity. Enrolling ineligible subjects compromises safety and data, making it a violation rather
than a minor deviation. Board Strategy: Violation = Major impact on safety/data; Deviation = Minor
procedural error.
Q8: ICH E6(R3) updates for 2026/2027 emphasize "Risk-Based Quality Management" (RBQM). What
does this approach require?
A. Auditing every single data point in the Case Report Form.
B. Focusing monitoring activities on critical data and processes essential to subject safety and data
integrity. [CORRECT]
C. Only visiting the site once every 3 years.
D. Relying solely on the PI's self-assessment.
Correct Answer: B
Rationale: RBQM shifts away from 100% source data verification (SDV) to a targeted approach. Sponsors
identify "Critical to Quality" factors (e.g., primary endpoint data, safety labs) and focus resources there.
Board Strategy: RBQM = Focus on critical data, not everything.
Q9: A subject in a psychiatric trial lacks the capacity to provide consent. Who can provide Legally
Authorized Representative (LAR) consent?
A. The treating physician.
EXAM 2026/2027 | CRL Certification
Complete Review | Verified Q&A |
Pass Guaranteed - A+ Graded
Section 1: Research Regulations & Ethics
Q1: The Belmont Report outlines three core ethical principles for the protection of human subjects.
Which principle requires that subjects be treated as autonomous agents and that persons with
diminished autonomy be protected?
A. Beneficence
B. Justice
C. Respect for Persons [CORRECT]
D. Non-maleficence
Correct Answer: C
Rationale: The Belmont Report defines "Respect for Persons" as having two components: treating
individuals as autonomous agents and providing extra protection for those with diminished autonomy
(e.g., children, prisoners). Beneficence relates to maximizing benefits and minimizing harms. Justice
relates to the fair distribution of the burdens and benefits of research. Board Strategy: Respect =
Autonomy.
Q2: According to ICH E6(R2) GCP guidelines, which party has the ultimate responsibility for the conduct
of a clinical trial at the site level?
A. The Sponsor
B. The Clinical Research Associate (CRA)
,C. The Institutional Review Board (IRB)
D. The Principal Investigator (PI) [CORRECT]
Correct Answer: D
Rationale: While the Sponsor is responsible for the overall trial, the Principal Investigator (PI) is
responsible for the conduct of the trial at their specific site. This includes the delegation of tasks,
oversight of staff, and protection of subjects. The IRB oversees ethics, not conduct. Board Strategy: Site
responsibility = PI.
Q3: A clinical trial subject calls the coordinator and states, "I want to stop the study." What is the
coordinator's most appropriate response?
A. "You have signed a contract; you must complete the study."
B. "You have the right to withdraw from the study at any time without penalty or loss of benefits to
which you are otherwise entitled." [CORRECT]
C. "You must come in for one final safety check before you can stop."
D. "I will have to report you to the Sponsor for protocol deviation."
Correct Answer: B
Rationale: A fundamental principle of GCP and the Declaration of Helsinki is that a subject can withdraw
from a study at any time for any reason without penalty. Requiring additional visits or threatening the
subject violates their rights. Board Strategy: Subject autonomy always comes first.
Q4: Which document serves as the basis for an investigator's financial disclosure?
A. Form FDA 1572 [CORRECT]
B. Form FDA 483
C. The Delegation Log
D. The Site Initiation Report
,Correct Answer: A
Rationale: Form FDA 1572 (Statement of Investigator) includes a section where the investigator discloses
financial interests that could affect the study's integrity. This form commits the investigator to follow
regulations and the protocol. Board Strategy: FDA 1572 = Investigator commitment & Financial
Disclosure.
Q5: Under 21 CFR Part 50, which of the following is a required element of Informed Consent?
A. A statement that the study involves no risk.
B. An explanation of the compensation available if injury occurs. [CORRECT]
C. A guarantee of the drug's efficacy.
D. The names of all other study participants.
Correct Answer: B
Rationale: The 8 required elements of informed consent include an explanation of whether
compensation or medical treatment is available if injury occurs. There is no such thing as "no risk,"
efficacy is never guaranteed, and other participants' names are confidential. Board Strategy: Memorize
the 8 basic elements of consent.
Q6: What is the primary purpose of an Institutional Review Board (IRB)?
A. To ensure the scientific validity of the protocol.
B. To protect the rights, safety, and well-being of human subjects. [CORRECT]
C. To manage the financial aspects of the trial.
D. To recruit subjects for the study.
Correct Answer: B
Rationale: The IRB (or Ethics Committee) acts as a subject advocate. Their primary function is ethical
review to ensure subjects are protected. Scientific validity is the Sponsor's primary duty (though IRBs
review it for ethics). Board Strategy: IRB = Subject Protection.
, Q7: A monitor discovers that a PI is enrolling subjects who do not meet the inclusion criteria. This is
classified as:
A. A Protocol Deviation.
B. A Protocol Violation. [CORRECT]
C. An Adverse Event.
D. An Amendment.
Correct Answer: B
Rationale: A violation is a serious departure from the protocol that affects the subject's rights, safety, or
data integrity. Enrolling ineligible subjects compromises safety and data, making it a violation rather
than a minor deviation. Board Strategy: Violation = Major impact on safety/data; Deviation = Minor
procedural error.
Q8: ICH E6(R3) updates for 2026/2027 emphasize "Risk-Based Quality Management" (RBQM). What
does this approach require?
A. Auditing every single data point in the Case Report Form.
B. Focusing monitoring activities on critical data and processes essential to subject safety and data
integrity. [CORRECT]
C. Only visiting the site once every 3 years.
D. Relying solely on the PI's self-assessment.
Correct Answer: B
Rationale: RBQM shifts away from 100% source data verification (SDV) to a targeted approach. Sponsors
identify "Critical to Quality" factors (e.g., primary endpoint data, safety labs) and focus resources there.
Board Strategy: RBQM = Focus on critical data, not everything.
Q9: A subject in a psychiatric trial lacks the capacity to provide consent. Who can provide Legally
Authorized Representative (LAR) consent?
A. The treating physician.
